By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for Lapachone
Email this page to a colleague
What is the development status for investigational drug Lapachone?
Lapachone is an investigational drug.
There have been 6 clinical trials for Lapachone.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2011.
The most common disease conditions in clinical trials are Metabolic Syndrome X, Pancreatic Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are University of Texas Southwestern Medical Center, KT&G Life Sciences Corp, and KT&G Corporation.
Summary for Lapachone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,518 |
| WIPO Patent Applications | 917 |
| Japanese Patent Applications | 615 |
| Clinical Trial Progress | Phase 1 (2011-04-01) |
| Vendors | 76 |
Recent Clinical Trials for Lapachone
| Title | Sponsor | Phase |
|---|---|---|
| ARQ761 + PARP Inhibitor in Refractory Solid Tumors | University of Texas Southwestern Medical Center | Phase 1 |
| ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | University of Texas Southwestern Medical Center | Phase 1 |
| Clinical Trial of ARQ 761 in Advanced Solid Tumors | ArQule | Phase 1 |
Clinical Trial Summary for Lapachone
Top disease conditions for Lapachone
Top clinical trial sponsors for Lapachone
US Patents for Lapachone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
